Propanc Biopharma, Inc.
PPCB
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.11M
Close$
$0.70
110.7% upside
Current Fair Value
110.7% upsideUndervalued by 110.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.11 Million |
|---|---|
| Enterprise Value | $783,715.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-17.62 |
| Beta | 3.33 |
| Outstanding Shares | 3,310,827 |
Return
| Return on Equity | -200.63% |
|---|---|
| Return on Assets | -147.60% |
| Return on Invested Capital | -184.01% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | -0.15 |
| Price to Sales | - |
| Price to Book Ratio | 0.17 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.05 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.65 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Propanc Biopharma, Inc.
2 employees
CEO: James Nathanielsz Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading ...